Company research
KORU Medical Systems, Inc.
CIK 704440Updated Nov 15, 2026
SecurityKRMD · NASDAQ · equity
Historical securities (1)
REPR · OTC · equity · closed Oct 17, 2019Name history
REPRO MED SYSTEMS INC · through Jun 3, 2022
KRMD price & chart
Loading TradingView…
NASDAQ:KRMD on TradingView ↗About the company
KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the “Freedom System”) currently includes the Freedom60® and FreedomEDGE® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HigH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Pharma Service and Clinical Trials business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit www.korumedical.com.
In the news
No coverage from other publishers is available.
Seeking Alpha
KORU Is On The Mend ↗
KORU medical systems raises 2026 revenue outlook to $48.0M-$48.5M while targeting year-end cash above $8M ↗
SEC disclosures
KORU Medical Systems, Inc. files 8-K: Material Event ↗
Recent filings
S-8 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
4 filing
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 5.03, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 27,103,526Source | 27,390,032Source | 27,962,013Source | 25,516,293Source | 27,303,566Source | 28,591,838Source | 27,216,167Source | 27,500,548Source | 28,200,179Source | 27,218,515Source | 28,460,972Source | 42,332,443Source |
| Property, Plant and Equipment, NetUSD | 4,235,983Source | 4,552,176Source | 3,929,718Source | 4,370,629Source | 3,678,984Source | 4,335,882Source | 4,533,949Source | 3,755,530Source | 4,471,386Source | 4,290,515Source | 3,837,657Source | 3,886,975Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 8,464,019Source | 8,806,310Source | 8,287,704Source | 8,054,716Source | 10,458,001Source | 8,767,774Source | 8,735,834Source | 10,820,317Source | 8,872,212Source | 9,580,947Source | 11,482,240Source | 17,408,257Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 5,412,004Source | 5,164,700Source | — | 4,929,071Source | 5,846,082Source | 5,982,536Source | 5,949,411Source | 4,392,511Source | 6,209,950Source | 5,720,750Source | 4,045,211Source | 3,558,884Source |
| Inventory, NetUSD | 4,411,710Source | 3,928,318Source | 4,511,126Source | 3,947,843Source | 2,588,750Source | 4,476,304Source | 3,278,646Source | 3,147,312Source | 3,678,131Source | 2,803,669Source | 3,481,301Source | 6,404,867Source |
| Assets, CurrentUSD | 19,419,296Source | 18,928,853Source | 19,514,117Source | 17,579,344Source | 19,365,697Source | 20,588,434Source | 18,999,028Source | 19,479,262Source | 19,988,790Source | 19,132,410Source | 20,255,929Source | 29,801,636Source |
| Operating Lease, Right-of-Use AssetUSD | 2,667,656Source | 3,063,731Source | 2,755,890Source | 2,768,376Source | 3,414,831Source | 2,857,341Source | 2,867,894Source | 3,428,885Source | 2,956,192Source | 2,966,341Source | 3,514,055Source | 3,786,545Source |
| Other Assets, NoncurrentUSD | 98,970Source | 98,970Source | 98,970Source | 98,970Source | 98,970Source | 98,970Source | 98,970Source | 98,970Source | 98,970Source | 98,970Source | 98,970Source | 102,625Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 10,638,701Source | 9,656,552Source | 9,910,496Source | 8,989,919Source | 8,599,016Source | 11,669,484Source | 10,871,136Source | 8,383,017Source | 11,152,257Source | 10,404,836Source | 8,107,201Source | 11,006,480Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 497,137Source | 492,758Source | 501,724Source | 496,555Source | 492,398Source | 499,335Source | 495,615Source | 491,436Source | 497,909Source | 493,776Source | 490,899Source | 488,619Source |
| Retained Earnings (Accumulated Deficit)USD | -31,529,976Source | -27,817,763Source | -32,571,461Source | -30,752,010Source | -26,236,946Source | -32,823,910Source | -30,545,143Source | -25,248,231Source | -32,016,832Source | -29,378,906Source | -23,312,273Source | -9,571,211Source |
| Stockholders' Equity Attributable to ParentUSD | 16,464,825Source | 17,733,480Source | 18,051,517Source | 16,526,374Source | 18,704,550Source | 16,922,354Source | 16,345,031Source | 19,117,531Source | 17,047,922Source | 16,813,679Source | 20,353,771Source | 31,325,963Source |
| Additional Paid in Capital, Common StockUSD | 51,380,158Source | 48,940,978Source | 56,527,047Source | 50,664,323Source | 48,331,591Source | 54,795,722Source | 50,277,053Source | 47,717,888Source | 52,449,339Source | 49,581,303Source | 47,018,707Source | 44,252,117Source |
| Liabilities and EquityUSD | 27,103,526Source | 27,390,032Source | 27,962,013Source | 25,516,293Source | 27,303,566Source | 28,591,838Source | 27,216,167Source | 27,500,548Source | 28,200,179Source | 27,218,515Source | 28,460,972Source | 42,332,443Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 7,833,932Source | 6,324,123Source | 7,179,822Source | 6,050,774Source | 5,136,840Source | 8,851,809Source | 7,799,277Source | 4,852,927Source | 8,194,358Source | 7,201,820Source | 4,454,278Source | 6,958,940Source |
| Operating Lease, Liability, CurrentUSD | 413,486Source | 395,954Source | 430,173Source | 409,019Source | 391,699Source | 421,727Source | 404,613Source | 372,109Source | 413,448Source | 400,258Source | 368,313Source | 345,834Source |
| Accounts Payable, CurrentUSD | 1,872,162Source | 1,670,300Source | 2,912,589Source | 1,094,539Source | 1,595,691Source | 2,635,701Source | 2,013,578Source | 1,774,185Source | 2,267,473Source | 1,649,969Source | 975,193Source | 2,391,799Source |
| Operating Lease, Liability, NoncurrentUSD | 2,688,490Source | 3,102,097Source | 2,659,265Source | 2,793,676Source | 3,202,697Source | 2,771,115Source | 2,897,600Source | 3,241,837Source | 2,879,224Source | 3,000,403Source | 3,336,300Source | 3,653,257Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 4,634,183Source | 2,792,967Source | 2,869,568Source | 3,635,525Source | 2,144,722Source | 5,271,100Source | 3,977,987Source | 1,459,405Source | 4,828,830Source | 3,924,184Source | 1,711,427Source | 2,889,941Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 1,362,235Source | 1,236,192Source | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | 204,482Source | 227,785Source | 210,031Source | 209,487Source | 197,531Source | 217,357Source | 810,500Source | 888,473Source | 870,390Source | 587,137Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 681,510Source | 697,590Source | 2,713,539Source | 2,623,920Source | 2,768,870Source | 3,079,427Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -227,414Source | 228,661Source | 489,199Source | 1,675,540Source | 486,327Source | -34,002Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 798,173Source | 474,977Source | 874,462Source | -677,632Source | -2,923,566Source | 298,529Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 368,228Source | 363,608Source | 617,504Source | 674,776Source | -1,416,606Source | 1,164,266Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 14,663Source | -237,467Source | 462,405Source | -319,718Source | -4,892,553Source | -5,404,549Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -89,885Source | -446,838Source | -949,790Source | -1,333,042Source | -814,597Source | -2,801,568Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -29,216Source | -160,808Source | -221,350Source | -248,533Source | -218,867Source | 279,485Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -104,438Source | -845,113Source | -708,735Source | -1,901,293Source | -5,926,017Source | -7,926,632Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 2,155Source | 5,385Source | 55,546Source | 71,934Source | 50,832Source | 28,490Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 14,850Source | — | 3,160Source | — |
| Additional Financial Items | ||||||||||||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 11,790Source | 9,485Source | -22,343Source | 44,193Source | -23,150Source | 5,588Source | 53,097Source | -45,991Source | -5,124Source | -39,874Source |
| Gain (Loss) on Disposition of Other AssetsUSD | — | — | — | — | -406,269Source | — | — | — | 6,700Source | -16,160Source | -59,807Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | -16,160Source | -59,807Source | — |
| Income Tax Expense (Benefit)USD | — | — | -150Source | — | 5,800Source | 17,356Source | — | — | 21,890Source | 2,893Source | 3,967,480Source | -2,014,018Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -777,966Source | -1,580,817Source | 252,449Source | -206,867Source | -807,078Source | -1,166,237Source | -2,637,926Source | -6,066,633Source | -13,741,062Source | -8,661,142Source |
| Nonoperating Income (Expense)USD | — | — | 89,563Source | 122,480Source | -368,742Source | 123,144Source | 57,845Source | 78,768Source | 356,406Source | 382,491Source | 496,397Source | 105,713Source |
| Operating ExpensesUSD | — | — | 7,132,250Source | 6,889,288Source | 7,219,217Source | 6,788,424Source | 8,096,312Source | 7,291,340Source | 28,576,521Source | 27,778,089Source | 26,978,261Source | 26,149,859Source |
| Other Nonoperating Income (Expense)USD | — | — | 3,206Source | — | — | 78,951Source | — | 73,180Source | 9,906Source | 444,642Source | 561,328Source | 145,587Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | — | 406,623Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | 186,165Source | — | — | — |
| Deferred Income Tax Expense (Benefit) | — | — | — | — | — | — | — | —Source | — | — | — | — |
| Depreciation | — | — | — | —Source | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 10,402,163Source | 8,179,977Source | 12,045,420Source | 10,194,800Source | 11,764,624Source | 9,635,075Source | 41,127,366Source | 33,646,463Source | 28,517,666Source | 27,896,037Source |
| Cost of RevenueUSD | — | — | 4,137,592Source | 2,993,986Source | 4,199,212Source | 3,719,031Source | 4,533,235Source | 3,588,740Source | 15,523,287Source | 12,314,605Source | 11,809,384Source | 12,527,051Source |
| Selling, General and Administrative ExpenseUSD | — | — | 5,994,661Source | 5,127,658Source | 5,939,986Source | 5,384,148Source | 6,582,178Source | 5,959,374Source | 23,378,807Source | 21,631,674Source | 20,365,617Source | 20,606,507Source |
| Operating Income (Loss)USD | — | — | -867,679Source | -1,703,297Source | 626,991Source | -312,655Source | -864,923Source | -1,245,005Source | -2,972,442Source | -6,446,231Source | -10,269,979Source | -10,780,873Source |
| Other Nonoperating Income (Expense)USD | — | — | 3,206Source | — | — | 78,951Source | — | 73,180Source | 9,906Source | 444,642Source | 561,328Source | 145,587Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -778,116Source | -1,580,817Source | 258,249Source | -189,511Source | -807,078Source | -1,166,237Source | -2,616,036Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | -150Source | — | 5,800Source | 17,356Source | — | — | 21,890Source | 2,893Source | 3,967,480Source | -2,014,018Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -777,966Source | -1,580,817Source | 252,449Source | -206,867Source | -807,078Source | -1,166,237Source | -2,637,926Source | -6,066,633Source | -13,741,062Source | -8,661,142Source |
| Earnings Per Share, BasicUSD per share | — | — | — | -0.03Source | 0.01Source | 0Source | -0.02Source | -0.03Source | -0.06Source | -0.13Source | -0.3Source | -0.19Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0.02Source | 0.03Source | 0.01Source | 0Source | -0.02Source | -0.03Source | -0.06Source | -0.13Source | -0.3Source | -0.19Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | — | 45,851,019Source | 46,083,893Source | 46,193,709Source | 46,364,905Source | 45,981,826Source | 46,187,077Source | 45,802,701Source | 45,601,346Source | 45,002,074Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 46,238,819Source | 45,851,019Source | 49,509,437Source | 46,193,709Source | 46,364,905Source | 45,981,826Source | 46,187,077Source | 45,802,701Source | 45,601,346Source | 45,002,074Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -21,890Source | -2,893Source | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 11,790Source | 9,485Source | -22,343Source | 44,193Source | -23,150Source | 5,588Source | 53,097Source | -45,991Source | -5,124Source | -39,874Source |
| Gross ProfitUSD | — | — | 6,264,571Source | 5,185,991Source | 7,846,208Source | 6,475,769Source | 7,231,389Source | 6,046,335Source | 25,604,079Source | 21,331,858Source | 16,708,282Source | 15,368,986Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -2,616,036Source | -6,063,740Source | — | — |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 74,567Source | 112,995Source | 59,870Source | 78,951Source | 80,995Source | 73,180Source | 293,403Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | 89,563Source | 122,480Source | -368,742Source | 123,144Source | 57,845Source | 78,768Source | 356,406Source | 382,491Source | 496,397Source | 105,713Source |
| Operating ExpensesUSD | — | — | 7,132,250Source | 6,889,288Source | 7,219,217Source | 6,788,424Source | 8,096,312Source | 7,291,340Source | 28,576,521Source | 27,778,089Source | 26,978,261Source | 26,149,859Source |
| Research and Development ExpenseUSD | — | — | 933,107Source | 1,533,845Source | 1,069,200Source | 1,194,789Source | 1,316,603Source | 1,114,609Source | 4,387,214Source | 5,257,942Source | 5,742,254Source | 4,956,215Source |
Filing attachments
ex_107.htm · S-8 · 2026-11-12
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 KORU Medical Systems, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Notes Fee Calculation Amount Registered Proposed Maximum Offering Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Rule Price…
Read attachment ↗ex_99-1.htm · 8-K · 2026-11-10
EXHIBIT 99.1 KORU Medical Systems Announces Third Quarter 2026 Results Including Second Consecutive Quarter of Positive Net Income and Adjusted EBITDA MAHWAH, NJ - November 10, 2026 - KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the third quarter …
Read attachment ↗ex_99-1.htm · 8-K · 2026-08-05
EX-99 2 ex_99-1.htm PRESS RELEASE, DATED AUGUST 5, 2026 EXHIBIT 99.1 KORU Medical Systems Announces Second Quarter 2026 Results and Updates Full Year 2026 Guidance MAHWAH, NJ - August 5, 2026 - KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the …
Read attachment ↗ex_99-1.htm · 4 · 2026-07-01
EXHIBIT 99.1 TO FORM 4 Explanation of Responses: (1) On June 30, 2026, Horton Capital Partners Fund, LP, a Delaware limited partnership (“HCPF”), was granted 3,472 shares of Koru Medical Systems, Inc. (the “Issuer”) common stock (“Common Stock”) in consideration for Mr. Manko’s service as a Director of the Issuer for the quarter ended June 30, 2026. (2) This Form 4 is filed jointly by Horton Capital Management, LLC, a Delaware limited liability co…
Read attachment ↗ex_99-1.htm · 8-K · 2026-05-06
EX-99 2 ex_99-1.htm PRESS RELEASE, DATED MAY 6, 2026 EXHIBIT 99.1 KORU Medical Systems Announces First Quarter 2026 Results MAHWAH, NJ - May 6, 2026 - KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the first quarter ended March 31, 2026. The Com…
Read attachment ↗ex_99-1.htm · 8-K · 2026-03-12
EX-99 2 ex_99-1.htm PRESS RELEASE, DATED MARCH 12, 2026 EXHIBIT 99.1 KORU Medical Systems Announces +20% Fourth Quarter and Full Year 2025 Revenue Growth, Positive Adjusted EBITDA and Initiates Full Year 2026 Guidance MAHWAH, NJ - March 12, 2026 - KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion so…
Read attachment ↗